ArticleImmunotherapy advances2026

PD-1 inhibitor-induced rheumatic, endocrine, and sarcoidosis-like immune-related adverse events in metastatic melanoma are associated with improved survival and lower corticosteroid exposure.

Maria Lindén et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.